| __timestamp | Bausch Health Companies Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 17986000 |
| Thursday, January 1, 2015 | 2682700000 | 32480000 |
| Friday, January 1, 2016 | 2810000000 | 68081000 |
| Sunday, January 1, 2017 | 2582000000 | 169906000 |
| Monday, January 1, 2018 | 2473000000 | 248932000 |
| Tuesday, January 1, 2019 | 2554000000 | 354100000 |
| Wednesday, January 1, 2020 | 2367000000 | 433300000 |
| Friday, January 1, 2021 | 2624000000 | 583300000 |
| Saturday, January 1, 2022 | 2625000000 | 752700000 |
| Sunday, January 1, 2023 | 2917000000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Bausch Health Companies Inc. over the past decade.
From 2014 to 2023, Bausch Health consistently reported higher SG&A expenses, peaking at approximately $2.9 billion in 2023. This represents a 44% increase from their 2014 figures. In contrast, Neurocrine Biosciences, Inc. exhibited a more dynamic growth trajectory, with SG&A expenses surging from a modest $18 million in 2014 to nearly $888 million in 2023, marking an astounding 4,800% increase.
These trends highlight Bausch Health's steady investment in operational activities, while Neurocrine's exponential growth suggests aggressive expansion and scaling efforts. Understanding these financial patterns offers valuable insights into each company's strategic priorities and market positioning.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?